CHEK2 and cancer: Based on the median posterior distribution of the log OR, we found that in patients with high CHK2 expression compared with patients with low CHK2 expression, the probabilities of an excellent response, NED in final follow-up, tumor size ≤10 mm, and classic cancer subtype were 0.34 to 1, 0.27 to 1, 0.43 to 1, and 0.34 to 1, respectively.